J Mandeli
Overview
Explore the profile of J Mandeli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
58
Citations
648
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Margolies L, Cohen A, Sonnenblick E, Mandeli J, Schmidt P, Szabo J, et al.
ISRN Radiol
. 2014 Jun;
2014:658929.
PMID: 24967297
Objectives. To study factors that predict changes in management with digital breast tomosynthesis (DBT). Methods. The Institutional Review Board approved this HIPAA compliant study. 996 patients had DBT with full...
2.
Altomonte J, Wu L, Meseck M, Chen L, Ebert O, Garcia-Sastre A, et al.
Cancer Gene Ther
. 2008 Oct;
16(3):266-78.
PMID: 18846115
Recombinant oncolytic viruses represent a promising alternative option for the treatment of malignant cancers. We have reported earlier the safety and efficacy of recombinant vesicular stomatitis virus (VSV) vectors in...
3.
Martinet O, Divino C, Zang Y, Gan Y, Mandeli J, Thung S, et al.
Gene Ther
. 2002 Jun;
9(12):786-92.
PMID: 12040460
We have shown that interleukin-12 (IL-12) generated a strong, albeit transient, anti-tumor response, mostly mediated by natural killer (NK) cell. T cell participation, in addition to NK cells, was essential...
4.
Platica M, Ivan E, Chen S, HOLLAND J, Gil J, Mandeli J, et al.
Prostate
. 2001 Dec;
49(3):200-7.
PMID: 11746265
Background: PAR is a novel gene ubiquitously expressed in normal and malignant tissues with a trend towards higher expression in tumor cells. PAR biological function is unknown. Here we report...
5.
Ferrari A, Chachoua A, Singh H, Rosenthal M, Taneja S, Bednar M, et al.
Cancer
. 2001 Jun;
91(11):2039-45.
PMID: 11391583
Background: The maximum tolerated dose (MTD) and efficacy of weekly 1-hour paclitaxel with 3 days of high dose oral estramustine were evaluated in patients with hormone-refractory prostate carcinoma. Methods: Patients...
6.
Zier K, Maddux J, Johnson K, Sung M, Mandeli J, Eisenbach L, et al.
Clin Cancer Res
. 2001 Apr;
7(3 Suppl):818s-821s.
PMID: 11300478
The increasing ability to augment antitumor immunity in model systems has led to increased numbers of clinical trials. However, progress in detecting immune responses by patients against autologous tumors has...
7.
Zier K, Johnson K, Maddux J, Sung M, Mandeli J, Eisenbach L, et al.
J Immunol Methods
. 2000 Aug;
241(1-2):61-8.
PMID: 10915849
Several issues remain to be resolved before the efficacy of various approaches to elicit anti-tumor immunity in patients can be evaluated. First, in vitro assays able to detect responses by...
8.
Martinet O, Ermekova V, Qiao J, Sauter B, Mandeli J, Chen L, et al.
J Natl Cancer Inst
. 2000 Jun;
92(11):931-6.
PMID: 10841829
Background: The success of immunomodulatory cancer therapy is frequently hampered by the transient nature of the antitumor immune response. We have shown previously in a mouse model that interleukin 12...
9.
Ben-Haim M, Mandeli J, Friedman R, Rosenthal R
J Surg Res
. 2000 Jun;
91(2):101-5.
PMID: 10839956
Introduction: In previous studies we described mechanisms by which acute elevation of the intraabdominal pressure (IAP) induces intracranial hypertension (ICHTN). Here we sought to define the role of ICHTN in...
10.
Sauter B, Martinet O, Zhang W, Mandeli J, Woo S
Proc Natl Acad Sci U S A
. 2000 Apr;
97(9):4802-7.
PMID: 10758166
Inhibition of angiogenesis has been shown to be an effective strategy in cancer therapy in mice. However, its widespread application has been hampered by difficulties in the large-scale production of...